{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:52:12Z","timestamp":1760147532926,"version":"build-2065373602"},"reference-count":65,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"French Society of Dermatology","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"Ligue Contre le Cancer Comit\u00e9 Dordogne","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"European Regional Development Fund","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"Programme Hubert Curien PESSOA","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"Programme d\u2019Actions Universitaires Int\u00e9gr\u00e9es Luso-Fran\u00e7aises (PAUILF)","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"Programme Hubert Curien CEDRE","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"ERASMUS+","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"FCT","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"Programme Hubert Curien CEDRE","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"\u201cCancer Research on Therapy Resistance: From Basic Mechanisms to Novel Targets\u201d","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"Norte Portugal Regional Operational Programme","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]},{"name":"\u201cThe Porto Comprehensive Cancer Center\u201d","award":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015","SFRH\/BD\/110617\/2015","NORTE-01-0145-FEDER-000051","NORTE 2020","NORTE-01-0145-FEDER-072678"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>As a major cancer hallmark, there is a sustained interest in understanding the telomerase contribution to carcinogenesis in order to therapeutically target this enzyme. This is particularly relevant in primary cutaneous T-cell lymphomas (CTCL), a malignancy showing telomerase dysregulation with few investigative data available. In CTCL, we examined the mechanisms involved in telomerase transcriptional activation and activity regulation. We analyzed 94 CTCL patients from a Franco-Portuguese cohort, as well as 8 cell lines, in comparison to 101 healthy controls. Our results showed that not only polymorphisms (SNPs) located at the promoter of human telomerase reverse transcriptase (hTERT) gene (rs2735940 and rs2853672) but also an SNP located within the coding region (rs2853676) could influence CTCL occurrence. Furthermore, our results sustained that the post-transcriptional regulation of hTERT contributes to CTCL lymphomagenesis. Indeed, CTCL cells present a different pattern of hTERT spliced transcripts distribution from the controls, mostly marked by an increase in the hTERT \u03b2+ variants proportion. This increase seems to be associated with CTCL development and progression. Through hTERT splicing transcriptome modulation with shRNAs, we observed that the decrease in the \u03b1-\u03b2+ transcript induced a decrease in the cell proliferation and tumorigenic capacities of T-MF cells in vitro. Taken together, our data highlight the major role of post-transcriptional mechanisms regulating telomerase non canonical functions in CTCL and suggest a new potential role for the \u03b1-\u03b2+ hTERT transcript variant.<\/jats:p>","DOI":"10.3390\/genes14020439","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T02:32:07Z","timestamp":1675909927000},"page":"439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Spotlight on hTERT Complex Regulation in Cutaneous T-Cell Lymphomas"],"prefix":"10.3390","volume":"14","author":[{"given":"Joana","family":"Ropio","sequence":"first","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"},{"name":"Institute of Biomedical Sciences of Abel Salazar, Porto University, 4050-313 Porto, Portugal"},{"name":"Faculty of Veterinary Medicine, Lus\u00f3fona University, 1749-024 Lisbon, Portugal"}]},{"given":"Martina","family":"Prochazkova-Carlotti","sequence":"additional","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"}]},{"given":"Rui","family":"Batista","sequence":"additional","affiliation":[{"name":"Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal"},{"name":"Faculty of Medicine, Porto University, 4200-319 Porto, Portugal"}]},{"given":"Ana","family":"Pestana","sequence":"additional","affiliation":[{"name":"Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal"},{"name":"Faculty of Medicine, Porto University, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5582-2923","authenticated-orcid":false,"given":"Alain","family":"Chebly","sequence":"additional","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"},{"name":"Medical Genetics Unit, Faculty of Medicine, Saint Joseph University, Beirut 1104 2020, Lebanon"},{"name":"Higher Institute of Public Health, Saint Joseph University, Beirut 1104 2020, Lebanon"}]},{"given":"Jacky","family":"Ferrer","sequence":"additional","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"}]},{"given":"Yamina","family":"Idrissi","sequence":"additional","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"}]},{"given":"David","family":"Cappellen","sequence":"additional","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"},{"name":"Tumor Bank and Tumor Biology Laboratory, Bordeaux University Hospital, 33075 Bordeaux, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9282-0708","authenticated-orcid":false,"given":"Cec\u00edlia","family":"Dur\u00e3es","sequence":"additional","affiliation":[{"name":"Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-8148","authenticated-orcid":false,"given":"Paula","family":"Boaventura","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-1427","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Vinagre","sequence":"additional","affiliation":[{"name":"Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal"}]},{"given":"Lamia","family":"Azzi-Martin","sequence":"additional","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"},{"name":"UFR des Sciences M\u00e9dicales, Bordeaux University, 33076 Bordeaux, France"}]},{"given":"Sandrine","family":"Poglio","sequence":"additional","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6232-1596","authenticated-orcid":false,"given":"Jos\u00e9","family":"Cabe\u00e7adas","sequence":"additional","affiliation":[{"name":"Dermatology Departement, Instituto Portugu\u00eas de Oncologia de Lisboa (IPO-L), 1099-023 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6810-790X","authenticated-orcid":false,"given":"Manuel Ant\u00f3nio","family":"Campos","sequence":"additional","affiliation":[{"name":"Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal"},{"name":"Faculty of Medicine, Porto University, 4200-319 Porto, Portugal"},{"name":"Centro Hospitalar Vila Nova de Gaia\/Espinho, E.P.E., Dermatology Departement, 4434-502 Vila Nova de Gaia, Portugal"}]},{"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"},{"name":"Dermatology Department, Bordeaux University Hospital, 33075 Bordeaux, France"}]},{"given":"Manuel","family":"Sobrinho-Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal"},{"name":"Faculty of Medicine, Porto University, 4200-319 Porto, Portugal"},{"name":"Department of Pathology, Faculty of Medicine, Porto University, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-0850","authenticated-orcid":false,"given":"Jean-Philippe","family":"Merlio","sequence":"additional","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"},{"name":"Tumor Bank and Tumor Biology Laboratory, Bordeaux University Hospital, 33075 Bordeaux, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-6998","authenticated-orcid":false,"given":"Paula","family":"Soares","sequence":"additional","affiliation":[{"name":"Institute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal"},{"name":"Faculty of Medicine, Porto University, 4200-319 Porto, Portugal"},{"name":"Department of Pathology, Faculty of Medicine, Porto University, 4200-319 Porto, Portugal"}]},{"given":"Edith","family":"Chevret","sequence":"additional","affiliation":[{"name":"BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.12688\/f1000research.11671.1","article-title":"Senescence and tumor suppression","volume":"6","author":"Hinds","year":"2017","journal-title":"F1000Research"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gaspar, T.B., S\u00e1, A., Lopes, J.M., Sobrinho-Sim\u00f5es, M., Soares, P., and Vinagre, J. (2018). Telomere maintenance mechanisms in cancer. Genes, 9.","DOI":"10.3390\/genes9050241"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"a003558","DOI":"10.1101\/cshperspect.a003558","article-title":"Telomerase: An RNP enzyme synthesizes DNA","volume":"3","author":"Blackburn","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0960-9822(00)00805-8","article-title":"The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo","volume":"10","author":"Liu","year":"2000","journal-title":"Curr. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12020-018-1642-0","article-title":"TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma","volume":"61","author":"Penna","year":"2018","journal-title":"Endocrine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.tibs.2013.07.001","article-title":"Telomerase: Central regulator of all of the hallmarks of cancer","volume":"38","author":"Low","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1111\/febs.12258","article-title":"Implications of telomere-independent activities of telomerase reverse transcriptase in human cancer","volume":"280","author":"Ding","year":"2013","journal-title":"FEBS J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1530\/JME-16-0195","article-title":"TERT biology and function in cancer: Beyond immortalisation","volume":"58","author":"Pestana","year":"2017","journal-title":"J. Mol. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12929-018-0422-8","article-title":"Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: Clinical impacts in cancer","volume":"25","author":"Lee","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1139\/o11-037","article-title":"Human telomerase expression regulation","volume":"89","author":"Gladych","year":"2011","journal-title":"Biochem. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Plyasova, A.A., and Zhdanov, D.D. (2021). Alternative Splicing of Human Telomerase Reverse Transcriptase (hTERT) and Its Implications in Physiological and Pathological Processes. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050526"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.gde.2013.11.005","article-title":"TERT promoter mutations in cancer development","volume":"24","author":"Heidenreich","year":"2014","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2018.12.003","article-title":"TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma","volume":"108","author":"Bournaud","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1103>3.0.CO;2-V","article-title":"Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development","volume":"91","author":"Ulaner","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Liu, X., Wang, Y., Chang, G., Wang, F., Wang, F., and Geng, X. (2017). Alternative splicing of hTERT Pre-mRNA: A potential strategy for the regulation of telomerase activity. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18030567"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1093\/nar\/29.23.4818","article-title":"Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells","volume":"29","author":"Yi","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1593\/neo.08644","article-title":"Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the \u03b2 deletion variant","volume":"10","author":"Lincz","year":"2008","journal-title":"Neoplasia"},{"key":"ref_21","first-page":"310","article-title":"Apoptotic endonuclease EndoG induces alternative splicing of telomerase catalytic subunit hTERT and death of tumor cells","volume":"10","author":"Zhdanov","year":"2016","journal-title":"Biochem. Suppl. Ser. B Biomed. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.neo.7900113","article-title":"An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity","volume":"2","author":"Yi","year":"2000","journal-title":"Neoplasia"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"S\u00e6b\u00f8e-Larssen, S., Fossberg, E., and Gaudernack, G. (2006). Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): Analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues. BMC Mol. Biol., 7.","DOI":"10.1186\/1471-2199-7-26"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/sj.neo.7900112","article-title":"The hTERT\u03b1 splice variant is a dominant negative inhibitor of telomerase activity","volume":"2","author":"Colgin","year":"2000","journal-title":"Neoplasia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/0008-5472.CAN-12-3082","article-title":"The major reverse transcriptase\u2013incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis","volume":"73","author":"Listerman","year":"2013","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12964-019-0372-0","article-title":"Diverse regulatory manners of human telomerase reverse transcriptase","volume":"17","author":"Jie","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/S146239941000147X","article-title":"Variation at the TERT locus and predisposition for cancer","volume":"12","author":"Baird","year":"2010","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_28","first-page":"612","article-title":"Telomere reverse transcriptase (TERT) rs2735940 increases cancer risk","volume":"21","author":"Yang","year":"2015","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbrc.2005.12.163","article-title":"Telomere length of normal leukocytes is affected by a functional polymorphism of hTERT","volume":"341","author":"Matsubara","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"50864","DOI":"10.18632\/oncotarget.15140","article-title":"Association between rs2853669 in TERT gene and the risk and prognosis of human cancer: A systematic review and meta-analysis","volume":"8","author":"Shen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Liu, Z., Wang, T., Wu, Z., Zhang, K., Li, W., Yang, J., Chen, C., Chen, L., and Xing, J. (2018). Association between TERT rs2853669 polymorphism and cancer risk: A meta-analysis of 9,157 cases and 11,073 controls. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191560"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/CEJ.0000000000000086","article-title":"Polymorphisms in the TERT gene are associated with lung cancer risk in the Chinese Han population","volume":"23","author":"Gao","year":"2014","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cao, J.-L., Yuan, P., Abuduwufuer, A., Lv, W., Yang, Y.-H., and Hu, J. (2015). Association between the TERT genetic polymorphism rs2853676 and cancer risk: Meta-analysis of 76 108 cases and 134 215 controls. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128829"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbrc.2006.07.103","article-title":"Coronary artery disease and a functional polymorphism of hTERT","volume":"348","author":"Matsubara","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ijc.30057","article-title":"The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism","volume":"139","author":"Batista","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"67203","DOI":"10.18632\/oncotarget.18226","article-title":"Functional dissection of breast cancer risk-associated TERT promoter variants","volume":"8","author":"Helbig","year":"2017","journal-title":"Oncotarget"},{"key":"ref_37","first-page":"1703","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11864-020-00809-w","article-title":"Mycosis fungoides and S\u00e9zary syndrome: Updates and review of current therapy","volume":"22","author":"Kamijo","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.17458","article-title":"How we treat advanced stage cutaneous T-cell lymphoma\u2013mycosis fungoides and S\u00e9zary syndrome","volume":"195","author":"Sethi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4274\/tjh.2016.0502","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: Clinical characteristics and prognosis","volume":"35","author":"Vural","year":"2018","journal-title":"Turk. J. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/cco.2018.11.02","article-title":"S\u00e9zary Syndrome, recent biomarkers and new drugs","volume":"8","author":"Cristofoletti","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers13081931","article-title":"Mycosis fungoides and s\u00e9zary syndrome: An integrative review of the pathophysiology, molecular drivers, and targeted therapy","volume":"13","author":"Piris","year":"2021","journal-title":"Cancers"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/DAD.0000000000001348","article-title":"Primary Cutaneous Anaplastic Lymphoma Kinase\u2013Positive Large B-Cell Lymphoma","volume":"41","author":"Kempf","year":"2019","journal-title":"Am. J. Dermatopathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-014-0061-9","article-title":"The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation","volume":"7","author":"Wang","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/genes7090061","article-title":"Telomerase activation in hematological malignancies","volume":"7","author":"Ropio","year":"2016","journal-title":"Genes"},{"key":"ref_46","first-page":"1850","article-title":"Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma","volume":"123","author":"Chevret","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41375-020-01068-2","article-title":"Xenograft and cell culture models of S\u00e9zary syndrome reveal cell of origin diversity and subclonal heterogeneity","volume":"35","author":"Poglio","year":"2021","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1002\/cam4.2816","article-title":"Reliable blood cancer cells\u2019 telomere length evaluation by qPCR","volume":"9","author":"Ropio","year":"2020","journal-title":"Cancer Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/1878-0261.12946","article-title":"Exploring hTERT promoter methylation in cutaneous T-cell lymphomas","volume":"16","author":"Chebly","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"775253","DOI":"10.3389\/fonc.2021.775253","article-title":"Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of S\u00e9zary Cells","volume":"11","author":"Chebly","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13073-016-0324-x","article-title":"Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies","volume":"8","author":"Jafri","year":"2016","journal-title":"Genome Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.leukres.2017.02.002","article-title":"Telomerase and telomere biology in hematological diseases: A new therapeutic target","volume":"56","author":"Allegra","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jnci\/djs222","article-title":"Telomerase reverse transcriptase locus polymorphisms and cancer risk: A field synopsis and meta-analysis","volume":"104","author":"Mocellin","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mrrev.2016.11.002","article-title":"TERT promoter mutations in telomere biology","volume":"771","author":"Heidenreich","year":"2017","journal-title":"Mutat. Res.\/Rev. Mutat. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"16663","DOI":"10.18632\/oncotarget.4389","article-title":"TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma","volume":"6","author":"Mosrati","year":"2015","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3109\/10428194.2012.729834","article-title":"Telomerase gene mutation screening and telomere overhang detection in Chinese patients with acute myeloid leukemia","volume":"54","author":"Yan","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"22886","DOI":"10.1038\/srep22886","article-title":"hTERT promotes cell adhesion and migration independent of telomerase activity","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jid.2016.04.027","article-title":"S\u00e9zary syndrome: Translating genetic diversity into personalized medicine","volume":"136","author":"Chevret","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_59","first-page":"1456","article-title":"Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures","volume":"138","author":"Herrera","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_60","first-page":"2539","article-title":"Improved S\u00e9zary cell detection and novel insights into immunophenotypic and molecular heterogeneity in S\u00e9zary syndrome","volume":"138","author":"Najidh","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Subasri, M., Shooshtari, P., Watson, A.J., and Betts, D.H. (2021). Analysis of TERT Isoforms across TCGA, GTEx and CCLE Datasets. Cancers, 13.","DOI":"10.3390\/cancers13081853"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/med.21674","article-title":"Targeting telomerase for its advent in cancer therapeutics","volume":"40","author":"Bajaj","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/nar\/gkh181","article-title":"Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing","volume":"32","author":"Gomez","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13046-018-0749-8","article-title":"Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461","volume":"37","author":"Li","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/2\/439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:28:51Z","timestamp":1760120931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/2\/439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":65,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["genes14020439"],"URL":"https:\/\/doi.org\/10.3390\/genes14020439","relation":{},"ISSN":["2073-4425"],"issn-type":[{"type":"electronic","value":"2073-4425"}],"subject":[],"published":{"date-parts":[[2023,2,8]]}}}